Jenkin D, Angyalfi S, Becker L, Berry M, Buncic R, Chan H, Doherty M, Drake J, Greenberg M, Hendrick B
Department of Hematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):215-25. doi: 10.1016/0360-3016(93)90342-s.
Eighty-seven consecutive children with newly diagnosed optic glioma were managed at University of Toronto hospitals 1958-1990. Overall the 10-year survival, relapse-free survival and freedom from second relapse rates were 84%, 68% and 85%. Twenty-seven patients relapsed or progressed, of whom 40% were free of a second relapse 10 years after the first relapse. Fourteen patients had a second relapse. Thirteen are dead. None survived 5 years after second relapse. Patients with anteriorly located tumors (N = 35), which involved the optic nerve, or chiasm and optic nerves, fared better than those with posteriorly located tumors (N = 52) with spread beyond the chiasm, 10-year survival 95% versus 76%, (p = .02), 10-year relapse-free survival 80% versus 59% (p = .02), respectively. For posterior tumors primary irradiation was more effective than primary subtotal resection for prevention of subsequent relapse, 10-year relapse-free survival 75% versus 41% (p = .02), but salvage therapy was, in part, successful and multivariate analysis of prognostic factors influencing survival for posterior tumors indicated that neither primary resection nor primary irradiation were significant factors. For first relapse, primary irradiation and the presence of neurofibromatosis were the significant favorable factors. Since 1977 and for posterior optic glioma subtotal resection or surveillance were used in 21/29 (72%) patients compared with 4/23 (17%) previously. Ten-year survival rates before and after 1977 were 78% and 67% and 10-year relapse-free survival 64% and 56%, respectively.
1958年至1990年期间,多伦多大学附属医院对87例新诊断的视神经胶质瘤患儿进行了治疗。总体而言,10年生存率、无复发生存率和无二次复发生存率分别为84%、68%和85%。27例患者复发或病情进展,其中40%在首次复发后10年无二次复发。14例患者出现二次复发。13例死亡。二次复发后无患者存活5年。肿瘤位于前部(N = 35),累及视神经、视交叉或视神经的患者,比肿瘤位于后部(N = 52)且扩散至视交叉以外的患者预后更好,10年生存率分别为95%和76%(p = 0.02),10年无复发生存率分别为80%和59%(p = 0.02)。对于后部肿瘤,原发性放疗在预防后续复发方面比原发性次全切除更有效,10年无复发生存率分别为75%和41%(p = 0.02),但挽救治疗部分成功,对影响后部肿瘤生存的预后因素进行多变量分析表明,原发性切除和原发性放疗均不是显著因素。对于首次复发,原发性放疗和神经纤维瘤病的存在是显著的有利因素。自1977年以来,对于后部视神经胶质瘤,21/29(72%)的患者采用了次全切除或观察,而之前这一比例为4/23(17%)。1977年前后的10年生存率分别为78%和67%,10年无复发生存率分别为64%和56%。